Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shield Therapeutics ( (GB:STX) ) just unveiled an update.
Shield Therapeutics reported a significant rise in revenues for 2024, reaching $32.2 million, with a notable 153% increase in ACCRUFeR® sales. The company aims to achieve cash flow positivity by the end of 2025 through strategic initiatives including a strengthened balance sheet and cost base streamlining. The recent $10 million equity funding and improved pricing strategy have positioned Shield favorably, particularly in the U.S. market, with ACCRUFeR® showing strong growth momentum.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company that focuses on addressing iron deficiency, with or without anemia, through its innovative product ACCRUFeR®/FeRACCRU® (ferric maltol). The company has partnered with Viatris Inc. for the U.S. market and has licensed rights in other regions including Europe, China, and Canada. ACCRUFeR® is the first FDA approved oral iron treatment for iron deficiency and iron deficiency anemia, addressing a significant unmet medical need.
YTD Price Performance: 5.56%
Average Trading Volume: 2,427,674
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £28.13M
For an in-depth examination of STX stock, go to TipRanks’ Stock Analysis page.